Myriad Women's Health provides the following resources in select languages:


Approximately 1 in 4 women may be at risk for hereditary cancer and meet current screening guidelines for testing.1 Myriad Women’s Health hereditary cancer genetic test myRisk™ provides actionable information, empowering patients and their families to make critical and timely healthcare decisions, reducing incidences of late onset cancers.

  • 90% of high-risk women are not screened for BRCA1/BRCA22
  • Interventions are proven to reduce risk3-6
  • ACOG, USPSTF, NCCN, & NPWH support hereditary cancer risk assessment as the standard of care7-9

Watch the video below and click the link to learn more

Fill out the form below and one of our Account Executives will contact you to discuss potential solutions that myRisk™ can provide for your patients.


1: DeFrancesco et al. Hereditary Cancer Risk Assessment and Genetic Testing in the CommunityPractice Setting. Obstetrics & Gynecology 2018 – published online before print October 10, 2018.
2: Bellcross CA, et al. Genet Med. 2015;17(1):43–50.
3: Hartmann, L. C. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340, 77–84 (1999).
4: Rebbeck, T. R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616–1622 (2002).
5: Plevritis, S et al. Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging. JAMA. 295(20), 2374–2384 (2006).
6: de Jong, A. E. et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130, 665–671 (2006).
7: ACOG Committee Opinion: Hereditary Cancer Syndromes and Risk Assessment, No. 634. June 2015, Reaffirmed 2017.
8: Risk assessment, genetic counseling, and genetic testing for BRCA related cancer in women: U.S. Preventive Services Task Force recommendation statement. JAMA. 2019;322(7):652-665. doi:10.1001/jama.2019.10987
9: Reference with permission from NCCN: Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic. Version 1.2020. © 2020 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed June 8, 2020. Available at